Preventative therapies for healthy women at high risk of breast cancer

References

• FerlayJSoerjomataramIErvikMGLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11 [Internet]LyonInternational Agency for Research on Cancer2013
   Google Scholar
• CuzickJAromatase inhibitors for breast cancer preventionJ Clin Oncol2005231636164315755971
   PubMed Web of Science ®Google Scholar
• TsengMWeinbergCRUmbachDMLongneckerMPCalculation of population attributable risk for alcohol and breast cancer (United States)Cancer Causes Control19991011912310231160
   PubMed Web of Science ®Google Scholar
• SestakICuzickJBreast cancer chemopreventionOncol Rev20082221226
   Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative GroupLancet1998351145114679605801
   PubMed Web of Science ®Google Scholar
• CuzickJPowlesTVeronesiUOverview of the main outcomes in breast-cancer prevention trialsLancet200336129630012559863
   PubMed Web of Science ®Google Scholar
• PowlesTEelesRAshleySInterim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trialLancet1998352981019672274
   PubMed Web of Science ®Google Scholar
• PowlesTJAshleySTidyASmithIEDowsettMTwenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trialJ Natl Cancer Inst20079928329017312305
   PubMed Web of Science ®Google Scholar
• CuzickJForbesJEdwardsRFirst results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trialLancet200236081782412243915
   PubMed Web of Science ®Google Scholar
• CuzickJForbesJFSestakILong-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trialJ Natl Cancer Inst20079927228217312304
   PubMed Web of Science ®Google Scholar
• VeronesiUMaisonneuvePRotmenszNTamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomyJ Natl Cancer Inst20079972773717470740
   PubMed Web of Science ®Google Scholar
• VeronesiUMaisonneuvePSacchiniVTamoxifen for breast cancer among hysterectomised womenLancet20023591122112411943263
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJPWickerhamDLTamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyJ Natl Cancer Inst2005971652166216288118
   PubMed Web of Science ®Google Scholar
• FisherBCostantinoJPWickerhamDLTamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst199890137113889747868
   PubMed Web of Science ®Google Scholar
• VeronesiUMaisonneuvePCostaAPrevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention StudyLancet199835293979672273
   PubMed Web of Science ®Google Scholar
• CuzickJSestakIBonanniBSelective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant dataLancet20133811827183423639488
   PubMed Web of Science ®Google Scholar
• CummingsSREckertSKruegerKAThe effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene EvaluationJAMA19992812189219710376571
   PubMed Web of Science ®Google Scholar
• MartinoSCauleyJABarrett-ConnorEContinuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifeneJ Natl Cancer Inst2004961751176115572757
   PubMed Web of Science ®Google Scholar
• Barrett-ConnorEMoscaLCollinsPEffects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenN Engl J Med200635512513716837676
   PubMed Web of Science ®Google Scholar
• VogelVGCostantinoJPWickerhamDLEffects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA2006295232727274116754727
   PubMed Web of Science ®Google Scholar
• CummingsSREnsrudKDelmasPDLasofoxifene in postmenopausal women with osteoporosisN Engl J Med201036268669620181970
   PubMed Web of Science ®Google Scholar
• CummingsSRMcClungMReginsterJYArzoxifene for prevention of fractures and invasive breast cancer in postmenopausal womenJ Bone Miner Res20112639740420658564
   PubMed Web of Science ®Google Scholar
• NICE: Familial Breast Cancer2013 Available from: guidance.nice.org.uk/cg164 NICE
   Google Scholar
• RichardsJAPetrelTABrueggemeierRWSignaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cellsJ Steroid Biochem Mol Biol20028020321211897504
   PubMed Web of Science ®Google Scholar
• BaumMBudzarAUCuzickJAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialLancet20023592131213912090977
   PubMed Web of Science ®Google Scholar
• BoccardoFRubagottiAPuntoniMSwitching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole TrialJ Clin Oncol2005235138514716009955
   PubMed Web of Science ®Google Scholar
• CoatesASKeshaviahAThürlimannBFive years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98J Clin Oncol20072548649217200148
   PubMed Web of Science ®Google Scholar
• CoombesRCHallEGibsonLJA randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancerN Engl J Med20043501081109215014181
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNMartinoSA randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerN Engl J Med20033491793180214551341
   PubMed Web of Science ®Google Scholar
• JakeszRJonatWGnantMSwitching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trialLancet200536645546216084253
   PubMed Web of Science ®Google Scholar
• MamounasEJeongJ-HWickerhamDLBenefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33Breast Cancer Res Treat2006100S22
   Web of Science ®Google Scholar
• BaumMBuzdarACuzickJAnastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analysesCancer2003981802181014584060
   PubMed Web of Science ®Google Scholar
• ArimidexTamoxifen Alone or in Combination (ATAC) Trialists’ GroupForbesJFCuzickJEffect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialLancet Oncol20089455318083636
   PubMed Web of Science ®Google Scholar
• HowellACuzickJBaumMResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancerLancet2005365606215639680
   PubMed Web of Science ®Google Scholar
• DowsettMCuzickJIngleJMeta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifenJ Clin Oncol20102850951819949017
   PubMed Web of Science ®Google Scholar
• GossPEIngleJNAlés-MartínezJEExemestane for breast-cancer prevention in postmenopausal womenN Engl J Med20113642381239121639806
   PubMed Web of Science ®Google Scholar
• CuzickJSestakIForbesJFAnastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trialLancet201438399221041104824333009
   PubMed Web of Science ®Google Scholar
• ChlebowskiRTColNBisphosphonates and breast cancer preventionAnticancer Agents Med Chem20121214415021864227
   PubMed Web of Science ®Google Scholar
• RennertGPinchevMRennertHSUse of bisphosphonates and risk of postmenopausal breast cancerJ Clin Oncol2010283577358120567021
   PubMed Web of Science ®Google Scholar
• TerryMBGammonMDZhangFFAssociation of frequency and duration of aspirin use and hormone receptor status with breast cancer riskJAMA20042912433244015161893
   PubMed Web of Science ®Google Scholar
• HolmesMDChenWYLiLHertzmarkESpiegelmanDHankinsonSEAspirin intake and survival after breast cancerJ Clin Oncol2010281467147220159825
   PubMed Web of Science ®Google Scholar
• LiYBraskyTMNieJUse of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosisCancer Epidemiol Biomarkers Prev20122123924222068285
   PubMed Web of Science ®Google Scholar
• WaldNJMorrisJKLawMRAspirin in the prevention of cancerLancet20113771649 author reply 1651–165221571138
   PubMed Web of Science ®Google Scholar
• CuzickJWarwickJPinneyETamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control studyJ Natl Cancer Inst201110374475221483019
   PubMed Web of Science ®Google Scholar
• KimJHanWMoonHGBreast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancerBreast Cancer Res201214R10222770227
   PubMed Web of Science ®Google Scholar
• RahmeEGhosnJDasguptaKRajanRHudsonMAssociation between frequent use of nonsteroidal anti-inflammatory drugs and breast cancerBMC Cancer2005515916343343
   PubMed Web of Science ®Google Scholar
• HarrisREBeebe-DonkJAlshafieGAReduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitorsBMC Cancer200662716445867
   PubMed Web of Science ®Google Scholar
• MazharDAngRWaxmanJCOX inhibitors and breast cancerBr J Cancer20069434635016421592
   PubMed Web of Science ®Google Scholar
• EliassenAHColditzGARosnerBWillettWCHankinsonSESerum lipids, lipid-lowering drugs, and the risk of breast cancerArch Intern Med20051652264227116246993
   PubMed Web of Science ®Google Scholar
• EssermanLJCampbellMShoemakerMBreast cancer inhibition by statinsProc Am Soc Clin Oncol2004200497
   Google Scholar
• MurilloGPengXTorresKEMehtaRGDeguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathwayCancer Prev Res (Phila)2009294295019861542
   PubMed Web of Science ®Google Scholar
• CuzickJBrentnallARSegalaCUse of a SNP panel to refine risk estimates in women at high risk of breast cancer: results from two randomized tamoxifen prevention trialsJ Clin Oncol201432Suppl abstr 1519
   Google Scholar